RLAY
Relay Therapeutics Inc (RLAY)
Healthcare • NASDAQ • $18.02+3.33%
- Symbol
- RLAY
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $18.02
- Daily Change
- +3.33%
- Market Cap
- $3.46B
- Trailing P/E
- N/A
- Forward P/E
- -9.62
- 52W High
- $17.47
- 52W Low
- $3.03
- Analyst Target
- $24.82
- Dividend Yield
- N/A
- Beta
- 1.75
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D.…
Company websiteResearch RLAY on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.